The Pfizer Research Grant supports interventional Investigator-Sponsored Research (ISR) aimed at generating clinical evidence for brentuximab vedotin in novel combination approaches for angioimmunoblastic T‑cell lymphoma (AITL) and peripheral T‑cell lymphoma–not otherwise specified (PTCL‑NOS).

Overview

This competitive grant program seeks proposals for interventional studies that address key clinical and scientific gaps in the use of brentuximab vedotin in AITL and PTCL‑NOS, irrespective of CD30 expression. Research should focus on evaluating the safety and efficacy of novel brentuximab vedotin–based combinations with therapies currently available for PTCL treatment. Proposed combinations must be supported by a clear scientific rationale grounded in mechanism of action and/or disease biology.

The geographic scope of this opportunity is limited to the United States.

Funding and Benefits

Individual projects requesting up to $500,000 will be considered. Pfizer anticipates supporting 1–2 projects. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. The maximum project length is 3 years.

Grant funding will be distributed following a fully executed agreement and submission of the final protocol, documentation of IRB/IEC approval, regulatory approval (if applicable), exemption, or waiver.

Eligibility

Geographic Scope: United States

Applicant Eligibility Criteria:

• The institution and Principal Investigator (PI) must be based in the United States.
• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
• If the project involves multiple departments within an institution and/or between different institutions or organizations, all must have a relevant role, and the requesting organization must have a key role.
• The PI must hold a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
• The applicant must be the PI or an authorized designee of such individual (e.g., the PI’s research coordinator).
• The PI must be an employee or contractor of the requesting organization.
• The requesting organization must be legally able to receive award funding directly from Pfizer Inc. Applicants should confirm this with their institution prior to submitting an application.
• Applicants must disclose whether artificial intelligence (AI) tools were used in preparing their grant application, identifying the tool(s), describing how they were used, and explaining how AI-assisted outputs were reviewed and validated. Failure to disclose may result in disqualification.

Research Areas

Primary Area of Interest: Oncology – Hematology – Peripheral T‑Cell Lymphomas (specifically AITL and PTCL‑NOS)

Studies should address key clinical and scientific gaps in the use of brentuximab vedotin in AITL and PTCL‑NOS irrespective of CD30 expression, with a focus on evaluating the safety and efficacy of novel brentuximab vedotin–based combinations with available PTCL therapies. The rationale must be grounded in mechanism of action and/or disease biology.

Application Process

Applications will be accepted via the online portal specified in the RFP. Project proposals and protocols should be single-spaced using Calibri 12-point font with 1-inch margins, and must not exceed 15 pages exclusive of references.

Full proposals must address the following sections:

• Goals and Objectives
• Assessment of Need for the Project (study rationale)
• Target Audience (including age, gender, and demographic information for trial population)
• Project Design and Methods (including inclusion/exclusion criteria, treatment plan, and statistical plan)
• Innovation
• Evaluation and Outcomes (safety, efficacy, and/or outcome measures; publication plan)
• Anticipated Project Timeline
• Additional Information
• Organization Detail
• Budget Detail (in USD)

Required documents include a Project Plan or Proposal and an Initial Study Protocol. Early-career applicants must include letter(s) of support from mentor(s) and collaborators.

Note: An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Deadline and Timeline

• RFP Release Date: July 15, 2026
• Submission Deadline: August 26, 2026 (23:59 Eastern Standard Time)
• Anticipated Grant Award Notification: September 16, 2026
• Anticipated Project Start Date: December 2026

Applications submitted after the due date will not be reviewed. The grant management system (CyberGrants) will be temporarily offline between July and August 2026 as part of a platform migration; updated submission instructions will be released at least one week prior to the deadline.

Contact Information

Questions regarding this RFP may be directed in writing to globalmedicalgrants@pfizer.com with the subject line “2026 ONC US PTCL RES”. Frequently asked questions about the Competitive Grant Program are available via Pfizer’s grants portal.